Treatment of Herpes Simplex Virus Type 2 (HSV-2) in Adults

Introduction to Treatment

The Centers for Disease Control and Prevention recommends oral antiviral medications such as acyclovir, valacyclovir, or famciclovir for adults with HSV-2 infection, with specific regimens depending on whether it is a first episode, recurrent episode, or suppressive therapy 1, 2

First Episode Treatment

For first-episode genital herpes, the American College of Obstetricians and Gynecologists recommends acyclovir 400 mg orally three times a day for 7-10 days, or acyclovir 200 mg orally five times a day for 7-10 days, or famciclovir 250 mg orally three times a day for 7-10 days, or valacyclovir 1 g orally twice a day for 7-10 days 2
Treatment may be extended if healing is incomplete after 10 days of therapy, as recommended by the Centers for Disease Control and Prevention 2
For severe mucocutaneous HSV lesions requiring hospitalization, the Infectious Diseases Society of America recommends intravenous acyclovir as the first-line therapy until lesions begin to regress, then transition to oral therapy 1, 3

Recurrent Episodes Treatment

For recurrent episodes, the Centers for Disease Control and Prevention recommends episodic therapy options including acyclovir 400 mg orally three times a day for 5-10 days, or valacyclovir 500 mg orally twice daily for 3-5 days 1, 2
Treatment should be initiated at the first sign of prodrome or genital lesions to maximize effectiveness, as recommended by the American College of Obstetricians and Gynecologists 2
Short-course therapy (1-3 days) should not be used in patients with HIV infection, according to the Centers for Disease Control and Prevention 1

Suppressive Therapy

The Centers for Disease Control and Prevention recommends suppressive therapy for persons who have frequent or severe recurrences (≥6 recurrences per year) 4, 5
Recommended suppressive regimens include valacyclovir 500 mg once daily for infrequent recurrences, or 1000 mg once daily for frequent recurrences (≥10 episodes per year), or valacyclovir 500 mg twice daily for HIV-infected persons, or acyclovir 400 mg twice daily 4, 5, 6
Suppressive therapy reduces recurrences by ≥75% and reduces asymptomatic viral shedding, which may decrease transmission risk, as reported by the Centers for Disease Control and Prevention 4

Special Considerations

For HIV-infected patients, the Centers for Disease Control and Prevention recommends higher doses and longer duration of treatment, and valacyclovir 500 mg twice daily for suppressive therapy 1, 6
For pregnant women, the American College of Obstetricians and Gynecologists recommends acyclovir as the first choice for therapy of HSV infections, and episodic therapy for first-episode HSV disease and recurrences can be offered during pregnancy 7
Cesarean delivery is recommended for women with genital herpes prodrome or visible lesions at the onset of labor, as recommended by the American College of Obstetricians and Gynecologists 7

Treatment Failure and Resistance

The Centers for Disease Control and Prevention recommends that treatment failure should be suspected if lesions do not begin to resolve within 7-10 days after initiation of therapy, and viral culture and susceptibility testing should be performed for suspected acyclovir-resistant HSV 4
The treatment of choice for acyclovir-resistant HSV is IV foscarnet, as recommended by the Infectious Diseases Society of America 4

Monitoring

The Centers for Disease Control and Prevention recommends no laboratory monitoring is needed in patients receiving episodic or suppressive therapy unless they have substantial renal impairment, and monitoring of renal function is recommended at initiation of treatment and once or twice weekly during treatment for patients receiving high-dose IV acyclovir 1

Patient Counseling

The American College of Obstetricians and Gynecologists recommends that patients should be counseled about the natural history of HSV-2, potential for recurrent episodes, asymptomatic viral shedding, and sexual transmission, and patients should abstain from sexual activity when lesions or prodromal symptoms are present, and condom use during all sexual exposures with new or uninfected partners should be encouraged 2

Suppressive Therapy in Pregnancy Without Recent or Current Outbreaks

Key Guideline Recommendations

The CDC explicitly states that episodic therapy for first-episode HSV disease and for recurrences can be offered during pregnancy, but suppressive therapy is not used routinely in pregnant women without frequent or severe recurrences 8, 9, 10
The American College of Obstetricians and Gynecologists, as reflected in CDC guidelines, recommends that suppressive antiviral therapy is NOT routinely recommended during pregnancy if you have no recent outbreaks and no outbreaks during the current pregnancy 8, 9, 10

When Suppressive Therapy IS Indicated in Pregnancy

Frequent, severe recurrences: If you have a documented history of frequent or severe recurrent genital HSV disease, acyclovir prophylaxis might be indicated, according to the American Academy of Family Physicians 11, 12
The CDC recommends that for women with a history of genital herpes but no recent or current outbreaks, suppressive therapy starting at 36 weeks gestation may be considered to reduce HSV shedding at delivery and decrease the need for cesarean delivery 8, 9, 10

Clinical Decision Algorithm

For women with history of genital herpes but no recent/current outbreaks: Before 36 weeks, no suppressive therapy is needed unless you have frequent, severe recurrences, as recommended by the American Academy of Family Physicians and the CDC 8, 11, 12
At labor onset: If visible lesions or prodromal symptoms are present, cesarean delivery is recommended regardless of prior suppressive therapy, according to the CDC 8, 9, 10

Safety Considerations

Acyclovir is the first-choice antiviral for HSV infections in pregnancy based on decades of safety data showing no pattern of adverse pregnancy outcomes, as stated by the CDC 8, 9, 10

Important Caveats

The primary goal is preventing neonatal transmission, which occurs mainly through maternal genital shedding at delivery, not through transplacental transmission, as emphasized by the CDC 8, 9, 10
HIV-infected pregnant women may have different considerations, though specific data on suppressive therapy to reduce HIV/HSV co-transmission is lacking, according to the CDC 8, 9, 10

Treatment of HSV-2 Without Active Outbreak

Recommended Suppressive Regimens

The Centers for Disease Control and Prevention recommends Acyclovir 400 mg twice daily as an alternative option for suppressive therapy 13

Important Clinical Considerations

After 1 year of continuous suppressive therapy, consider discontinuation to reassess the patient's natural recurrence rate, as suggested by the Centers for Disease Control and Prevention 13
No laboratory monitoring is needed unless the patient has substantial renal impairment, according to the Centers for Disease Control and Prevention 14

Critical Counseling Points

The Centers for Disease Control and Prevention advises that asymptomatic viral shedding occurs and transmission can happen even without visible lesions 13
Consistent condom use reduces transmission risk by approximately 50% and should be encouraged, as recommended by the Centers for Disease Control and Prevention 14
Partners should be tested using type-specific serology and counseled about transmission risks, according to the Centers for Disease Control and Prevention 14

Common Pitfalls to Avoid

The Centers for Disease Control and Prevention recommends not using short-course therapy (1-3 days) in HIV-infected patients, as it is ineffective 14
Do not assume treatment prevents all transmission—counsel patients that suppressive therapy reduces but does not eliminate transmission risk, as suggested by the Centers for Disease Control and Prevention 13
The Centers for Disease Control and Prevention advises not to forget to adjust doses in patients with renal impairment to prevent toxicity 14

Safety and Counseling for Genital Herpes in HIV‑Positive Pregnant Patients

Safety of Antiviral Therapy in Pregnancy

Maternal exposure to oral acyclovir during any trimester has not been linked to a higher incidence of adverse pregnancy outcomes or major congenital anomalies; registry and cohort data show no excess risk compared with the general population (Annals of Internal Medicine 1999) 15

Early Suppressive (Prophylactic) Therapy Considerations

In HIV‑infected pregnant women who have a documented pattern of frequent or severe recurrent genital HSV infections, initiating acyclovir prophylaxis before the standard 36‑week start may be warranted to further reduce maternal viral shedding at delivery (Annals of Internal Medicine 1999) 15

Patient Counseling on Sexual Activity

Women should be counseled to abstain from sexual intercourse whenever they experience active genital lesions or prodromal symptoms, as this practice lowers the risk of HSV transmission to sexual partners (Annals of Internal Medicine 1999) 15

CDC Recommendations for Clinical Management of HSV‑2 in Adults

Severe Disease Requiring Hospitalization

Initiate intravenous acyclovir at 5–10 mg/kg every 8 hours for patients with severe mucocutaneous lesions, disseminated infection, encephalitis, pneumonitis, or hepatitis, and transition to oral therapy once lesions begin to regress. [16]

Critical Patient Counseling at Diagnosis

Advise patients to refrain from all sexual activity while lesions or prodromal symptoms are present, to prevent transmission. [16]
Instruct women of reproductive age to inform their obstetric care providers about HSV‑2 infection so that pregnancy management can be appropriately planned. [16]

Therapeutic Pitfalls to Avoid

Do not use topical acyclovir as monotherapy because it is substantially less effective than systemic therapy and does not improve systemic symptoms. [16]

Partner Management

Recommend that sexual partners be evaluated and counseled, regardless of symptom status. [16]
Provide symptomatic partners with the same systemic antiviral regimen prescribed for patients with genital lesions. [16]
Query asymptomatic partners about any prior typical or atypical genital lesions and encourage regular self‑examination for future lesions. [16]